NCT06698887View on ClinicalTrials.gov

A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea

RecruitingOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

September 11, 2024

Primary Completion Date

March 27, 2031

Study Completion Date

March 27, 2031

Conditions
Multiple Myeloma
Interventions
DRUG

Idecabtagene vicleucel

As per CA089-1043 study protocol

Trial Locations (5)

58128

RECRUITING

Chonnam National University Hwasun Hospital, Hwasun

03080

RECRUITING

Seoul National University Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

06591

RECRUITING

The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06698887 - A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea | Biotech Hunter | Biotech Hunter